Format

Send to

Choose Destination
Lancet. 1990 Aug 18;336(8712):392-5.

Enhancement of recovery from psychiatric illness by methylfolate.

Author information

1
Department of Psychiatry, King's College Hospital and Institute of Psychiatry, London, UK.

Abstract

41 (33%) of 123 patients with acute psychiatric disorders (DSM III diagnosis of major depression or schizophrenia) had borderline or definite folate deficiency (red-cell folate below 200 micrograms/l) and took part in a double-blind, placebo-controlled trial of methylfolate, 15 mg daily, for 6 months in addition to standard psychotropic treatment. Among both depressed and schizophrenic patients methylfolate significantly improved clinical and social recovery. The differences in outcome scores between methylfolate and placebo groups became greater with time. These findings add to the evidence implicating disturbances of methylation in the nervous system in the biology of some forms of mental illness.

PMID:
1974941
DOI:
10.1016/0140-6736(90)91942-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center